Boehringer, Perosphere Anticoagulant Antidotes Advance At AHA
Executive Summary
At a time when demand for anticoagulant antidotes is high, the 2013 AHA meeting featured the first human data for two new reversal agents from Boehringer Ingelheim and Perosphere. Perosphere will be pursuing “breakthrough therapy” status with FDA for its intravenous small molecule candidate PER977.
You may also be interested in...
Daiichi’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
Answering The Call For Antidotes
Bad publicity about bleeding events spells headaches for drug developers, but also an opportunity for companies that can come up with antidotes to reverse anticoagulation effects.
The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote
Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.